Navigation Links
Effective ADHD treatment found for children with fragile X syndrome
Date:2/18/2008

Fragile X syndrome (FXS) is the most common hereditary form of mental retardation. Many children with FXS also suffer from attention deficit and/or hyperactivity disorder (ADHD), which complicates social relationships at home and at school. Although stimulant medication such as Ritalin is often successfully used to treat children with ADHD, studies have shown that while it is effective in children with mental retardation, it also causes side effects such as increased irritability, decreased verbalization and social withdrawal.

A previous study showed that L-acetyl carnitine (LAC), a form of the amino acid carnitine, significantly reduced hyperactive behavior in FXS boys with ADHD who were treated with it for one year without causing adverse side effects. The same authors have now conducted a randomized, double-blind, placebo-controlled multicenter study to determine the effectiveness of LAC in a larger group. The study is published in the April 1st, 2008 issue of the American Journal of Medical Genetics Part A, available online via Wiley InterScience at http://www3.interscience.wiley.com/cgi-bin/jhome/33129.

Led by M. Giulia Torrioli and Giovanni Neri of the Universit Cattolica in Rome, the study involved 51 boys between 6 and 12 years old with FXS and ADHD who were treated in one of eight centers in Italy, France and Spain. Each patient followed the treatment for 12 months, which involved 500 milligrams of LAC or a placebo given twice daily. Patients were evaluated by an interdisciplinary team of child neuropsychiatrists and psychologists at the start of the study, after one month, six months and 12 months. The effects of the drug and placebo were evaluated using a set of neuropsychological tests to assess behavior.

Those treated with LAC demonstrated reduced hyperactive behavior and increased attention. No side effects were exhibited, confirming that LAC is a safe alternative to stimulants. The patients treated with the placebo also showed reduced hyperactive behavior, although not nearly to the extent as the LAC-treated patients. The patients treated with LAC also had significantly improved social ability compared to the placebo-treated group. Both groups took intelligence tests, but LAC did not improve overall intellectual functioning.

We propose that LAC be recommended as a treatment of ADHD in FXS children, conclude the authors, since it effectively reduces hyperactive behavior and improves social abilities without adverse side effects. They also suggest that these results may be applicable to children with autism, who also do not easily tolerate stimulants.


'/>"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Blackwell Publishing Ltd.
Source:Eurekalert

Related biology news :

1. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
2. Safe and effective therapy discovered for patients with protein-losing enteropathy
3. Tamiflu effective for treatment and prevention of influenza in children 1 year and older
4. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
5. Quantitative PET imaging finds early determination of effectiveness of cancer treatment
6. New hope for horse lovers as effective control for killer ragwort is proposed
7. Trial seeks genetic fingerprint for predicting drug effectiveness
8. MIT model could improve some drugs effectiveness
9. New nanoparticle vaccine is more effective but less expensive
10. Socioeconomic position associated with effectiveness of HIV drugs
11. UC health news: molecular pathway may predict chemotherapy effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
(Date:3/20/2017)... 20, 2017 At this year,s CeBIT Chancellor Dr. ... manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with the ... year,s CeBIT partner country. At the largest German biometrics company the two ... face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... ... 2017 , ... RMC Pharmaceutical Solutions, Inc. announces the opening ... manage the new site. , Tim has 25 years of pharmaceutical experience, including ... as the Director of Manufacturing and Supplier Quality Assessment. This group is ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... to clients throughout the biopharma and life sciences industries, continue to be in ... seeing. Tunnell’s Kip Wolf will be speaking on “The State of Information Governance ...
(Date:6/20/2017)... ... June 20, 2017 , ... Biologist Dawn Maslar MS has found ... latest book, Men Chase, Women Choose: The Neuroscience of Meeting, Dating, Losing Your Mind, ... effect on men. ”The logical next step, in my estimation, was to scientifically track ...
(Date:6/20/2017)... Francisco, CA (PRWEB) , ... June 20, 2017 ... ... patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, announces launch ... Conference in San Diego, California. Dave Johnson, PhD, CEO of GigaGen, will present ...
Breaking Biology Technology: